A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy
This study is testing different combinations of chemotherapy and newer targeted medicines to see which works best for treating newly diagnosed, intermediate-risk acute myeloid leukemia in younger patients. Doctors want to find out if adding a drug called venetoclax can help clear the cancer better than standard treatment alone.
You might be able to join if you are a younger patient who has been newly diagnosed with intermediate-risk acute myeloid leukemia and have not received prior treatment for it. You also need to be registered in the MyeloMATCH master screening program and agree to share tissue or blood samples.
Participants will be assigned to receive different combinations of study medications, which may include standard chemotherapy and targeted drugs like venetoclax or azacitidine. You will also undergo regular check-ups, blood tests, bone marrow samples, and heart scans to monitor your health and how well the treatment is working.
This study is currently recruiting patients and has locations in states such as Alabama and Arizona, as part of a nationwide network.
- 1Testing new drug combinations to improve leukemia treatment for younger patients
- 2Compares standard chemotherapy against treatments that include the targeted drug venetoclax
- 3Involves regular health monitoring including heart scans and bone marrow tests
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.